Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA grants emergency use authorization to Jynneos monkeypox vaccine to support ‘dose sparing’

By Brian Buntz | August 9, 2022

FDA logoFDA has authorized emergency use of the Jynneos monkeypox vaccine for individuals who face an elevated risk of infection from the virus.

The authorization specifically allows the intradermal use of vaccine from Bavarian Nordic A/S (OMX:BAVA, OTC:BVNRY) in those 18 and older with a high risk of monkeypox infection.

The agency notes that the intradermal administration of the two-dose vaccine allows a fraction of the vaccine to be administered than would be delivered subcutaneously.

Expanding Jynneos monkeypox vaccine availability five-fold

Jynneos

[Image courtesy of Bavarian Nordic]

Last week, FDA Commissioner Dr. Robert Califf said the agency was considering this “dose sparing” strategy to allow more people to receive the vaccine.

FDA notes that the EUA will expand the availability of the vaccine by up to five-fold.

In 2019, the agency approved the vaccine to prevent smallpox and monkeypox in adults.

The latest move will bolster the U.S.’s efforts to ramp up monkeypox vaccination efforts, Califf said.

“In recent weeks, the monkeypox virus has continued to spread at a rate that has made it clear our current vaccine supply will not meet the current demand,” he said in a statement. “The FDA quickly explored other scientifically appropriate options to facilitate access to the vaccine for all impacted individuals.”

Data from a 2015 study underpins strategy

FDA decided to allow the intradermal use of the vaccine after reviewing data from a 2015 clinical study published in Vaccine. It concluded that a lower intradermal dose of modified vaccinia Ankara vaccine was “immunologically non-inferior to the standard subcutaneous dose.

Data from that study indicated that the immune response from the vaccine was similar whether delivered intradermally or subcutaneously.

There may be a cost in terms of side effects, however. When administered intradermally, the vaccine tended to cause more side effects at the injection site but less pain compared to subcutaneous administration.

An article on STAT News noted that the intradermal vaccination strategy may backfire, given questions about the effectiveness of Jynneos in the current monkeypox outbreak. Data suggest that the vaccine can reduce the severity of monkeypox infections but does not prevent infections or transmissions.

There are no data on the effectiveness of the Jynneos or the ACAM2000 vaccines in the current monkeypox outbreak.


Filed Under: Infectious Disease

 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

covid-19 vaccine
FDA COVID booster pullback jolts vaccine stocks before gains cool
Coronavirus Covid-19 background - 3d rendering
Pregnancy associated with less long COVID: Researchers call for studies on protective biology
How technology advances are helping scientists unlock the mysteries of zoonotic diseases
Novel coronovirus
Advances in next generation vaccine development for SARS-CoV-2
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE